Markets:

Overview

News

Currencies

International

Treasuries

Metagenomi, Inc. - Common Stock (NQ:MGX)

1.750 -0.040 (-2.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Metagenomi, Inc. - Common Stock

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗

November 12, 2025

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 12, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

November 11, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 11, 2025

Via Benzinga

Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts ↗

December 10, 2024

Via Benzinga

Peeling Back The Layers: Exploring Metagenomi Through Analyst Insights ↗

September 06, 2024

Via Benzinga

Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected ↗

August 12, 2025

Metagenomi Inc (NASDAQ:MGX) reported Q2 2025 earnings with revenue beating estimates at $8.51M and a narrower loss of -$0.54 per share. Shares dipped slightly amid investor caution over cash burn and...

Via Chartmill

Which stocks are gapping on Wednesday? ↗

July 09, 2025

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe ↗

June 20, 2025

OpenAI CEO Sam Altman regrets underestimating Elon Musk's potential abuse of power to block OpenAI's $500B Stargate deal. Tensions also rise with Microsoft.

Via Benzinga

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Unveiling 4 Analyst Insights On Metagenomi ↗

August 21, 2024

Via Benzinga

Demystifying Metagenomi: Insights From 4 Analyst Reviews ↗

May 15, 2025

Via Benzinga

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗

May 15, 2025

Via Benzinga

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week ↗

March 16, 2025

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

Via Stocktwits

Stargate, Netflix, GE Aerospace, Twilio, and More ↗

January 29, 2025

There's a lot for investors to talk about.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

January 22, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 09, 2024

Via Benzinga

Cogent Communications To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗

August 19, 2024

Via Benzinga

MGX Stock Earnings: Metagenomi Beats EPS, Beats Revenue for Q2 2024 ↗

August 14, 2024

MGX stock results show that Metagenomi beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024 ↗

May 14, 2024

MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars ↗

May 02, 2024

Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 02, 2024

Via Benzinga

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire ↗

May 02, 2024

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 19, 2024

Via Benzinga

This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet ↗

February 19, 2024

A bumpy start can't detract from this company's strong balance sheet.

Via The Motley Fool

Topics Initial Public Offering

Gilead-Backed Kyverna Overshoots Raised IPO Expectations ↗

February 11, 2024

Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a...

Via Talk Markets

Topics Initial Public Offering

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.